Dr. Reddy's Laboratories ... (RDY)
Dr. Reddy's Laboratories Statistics
Share Statistics
Dr. Reddy's Laboratories has 833.11M shares outstanding. The number of shares has increased by 0.06% in one year.
| Shares Outstanding | 833.11M |
| Shares Change (YoY) | 0.06% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | 14.21% |
| Shares Floating | 833.09M |
| Failed to Deliver (FTD) Shares | 29 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 18.45 and the forward PE ratio is 0.2. Dr. Reddy's Laboratories's PEG ratio is 0.8.
| PE Ratio | 18.45 |
| Forward PE | 0.2 |
| PS Ratio | 3.68 |
| Forward PS | 0 |
| PB Ratio | 3.66 |
| P/FCF Ratio | 57.09 |
| PEG Ratio | 0.8 |
Enterprise Valuation
Dr. Reddy's Laboratories has an Enterprise Value (EV) of 1,040.3B.
| EV / Sales | 3.73 |
| EV / EBITDA | 11.77 |
| EV / EBIT | 22.9 |
| EV / FCF | 57.8 |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.58 |
| Quick Ratio | 1.92 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | 1.11 |
| Interest Coverage | 39.58 |
Financial Efficiency
Return on Equity is 19.85% and Return on Invested Capital is 17.18%.
| Return on Equity | 19.85% |
| Return on Assets | 14.37% |
| Return on Invested Capital | 17.18% |
| Revenue Per Employee | $10.32M |
| Profits Per Employee | $2.06M |
| Employee Count | 27,048 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.82 |
Taxes
| Income Tax | 16.19B |
| Effective Tax Rate | 22.52% |
Stock Price Statistics
The stock price has increased by -7.51% in the last 52 weeks. The beta is 0.48, so Dr. Reddy's Laboratories's price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -7.51% |
| 50-Day Moving Average | 13.21 |
| 200-Day Moving Average | 14.83 |
| Relative Strength Index (RSI) | 58.11 |
| Average Volume (20 Days) | 2.17M |
Income Statement
In the last 12 months, Dr. Reddy's Laboratories had revenue of 279.16B and earned 55.68B in profits. Earnings per share was 66.8.
| Revenue | 279.16B |
| Gross Profit | 163.61B |
| Operating Income | 67.73B |
| Net Income | 55.68B |
| EBITDA | 88.42B |
| EBIT | 73.58B |
| Earnings Per Share (EPS) | 66.8 |
Balance Sheet
The company has 7.11B in cash and 20.02B in debt, giving a net cash position of -12.91B.
| Cash & Cash Equivalents | 7.11B |
| Total Debt | 20.02B |
| Net Cash | -12.91B |
| Retained Earnings | 265.26B |
| Total Assets | 481.06B |
| Working Capital | 121.07B |
Cash Flow
In the last 12 months, operating cash flow was 45.43B and capital expenditures -27.43B, giving a free cash flow of 18B.
| Operating Cash Flow | 45.43B |
| Capital Expenditures | -27.43B |
| Free Cash Flow | 18B |
| FCF Per Share | 21.59 |
Margins
Gross margin is 58.61%, with operating and profit margins of 24.26% and 19.95%.
| Gross Margin | 58.61% |
| Operating Margin | 24.26% |
| Pretax Margin | 25.74% |
| Profit Margin | 19.95% |
| EBITDA Margin | 31.67% |
| EBIT Margin | 24.26% |
| FCF Margin | 6.45% |
Dividends & Yields
RDY pays an annual dividend of $0.1, which amounts to a dividend yield of 0.59%.
| Dividend Per Share | $0.10 |
| Dividend Yield | 0.59% |
| Dividend Growth (YoY) | -1.84% |
| Payout Ratio | 12.61% |
| Earnings Yield | 5.42% |
| FCF Yield | 1.75% |
Analyst Forecast
The average price target for RDY is $17, which is 23.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $17 |
| Price Target Difference | 23.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 5, 2024. It was a forward split with a ratio of 5:1.
| Last Split Date | Nov 5, 2024 |
| Split Type | forward |
| Split Ratio | 5:1 |
Scores
| Altman Z-Score | 2.36 |
| Piotroski F-Score | 4 |